448 related articles for article (PubMed ID: 21882396)
1. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman M; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D; ;
Atherosclerosis; 2011 Jul; 217(1):3-46. PubMed ID: 21882396
[No Abstract] [Full Text] [Related]
2. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D;
Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445
[No Abstract] [Full Text] [Related]
3. The new joint EAS/ESC guidelines for the management of dyslipidaemias.
Catapano AL; Chapman J; Wiklund O; Taskinen MR
Atherosclerosis; 2011 Jul; 217(1):1. PubMed ID: 21722901
[No Abstract] [Full Text] [Related]
4. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).
; Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
Atherosclerosis; 2016 Oct; 253():281-344. PubMed ID: 27594540
[No Abstract] [Full Text] [Related]
5. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
; Reiner Z; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D;
Eur Heart J; 2011 Jul; 32(14):1769-818. PubMed ID: 21712404
[TBL] [Abstract][Full Text] [Related]
6. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WMM; Vlachopoulos C; Wood DA; Zamorano JL; Cooney MT;
Eur Heart J; 2016 Oct; 37(39):2999-3058. PubMed ID: 27567407
[No Abstract] [Full Text] [Related]
7. [ECS guidelines 2016 - dyslipidaemias].
Sinning D; Landmesser U
Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
[TBL] [Abstract][Full Text] [Related]
8. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).
Kristensen SD; Knuuti J; Saraste A; Anker S; Bøtker HE; De Hert S; Ford I; Gonzalez Juanatey JR; Gorenek B; Heyndrickx GR; Hoeft A; Huber K; Iung B; Kjeldsen KP; Longrois D; Luescher TF; Pierard L; Pocock S; Price S; Roffi M; Sirnes PA; Uva MS; Voudris V; Funck-Brentano C;
Eur J Anaesthesiol; 2014 Oct; 31(10):517-73. PubMed ID: 25127426
[No Abstract] [Full Text] [Related]
9. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].
Catapano AL; Averna M; Faggiano P; Novo S
G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730
[No Abstract] [Full Text] [Related]
10. [A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].
Ural D
Turk Kardiyol Dern Ars; 2012 Jun; 40(4):293-7. PubMed ID: 22951844
[No Abstract] [Full Text] [Related]
11. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
Reiner Z
Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
[No Abstract] [Full Text] [Related]
12. [Comments on the ESC/EAS guidelines for the management of dyslipidaemias 2011. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology].
Anguita M; Alegría E; Barrios V; Casasnovas JA; Escobar C; León M; Luengo E; Llisterri JL; Alonso Á; Cequier Á; Comín J; Fernández-Ortiz A; Heras M; Pan M; Worner F
Rev Esp Cardiol; 2011 Dec; 64(12):1090-5. PubMed ID: 22107831
[No Abstract] [Full Text] [Related]
13. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].
Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
Kardiol Pol; 2016; 74(11):1234-1318. PubMed ID: 27910077
[No Abstract] [Full Text] [Related]
14. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: What is new?].
Kayıkçıoğlu M; Tokgözoğlu L
Turk Kardiyol Dern Ars; 2017 Mar; 45(2):109-112. PubMed ID: 28424431
[No Abstract] [Full Text] [Related]
15. Lipid Clinics Network. Rationale and design of the EAS global project.
Alieva AS; Tokgözoğlu L; Ray KK; Catapano AL
Atheroscler Suppl; 2020 Dec; 42():e6-e8. PubMed ID: 33589226
[TBL] [Abstract][Full Text] [Related]
16. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
17. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement.
Hegele RA; Borén J; Ginsberg HN; Arca M; Averna M; Binder CJ; Calabresi L; Chapman MJ; Cuchel M; von Eckardstein A; Frikke-Schmidt R; Gaudet D; Hovingh GK; Kronenberg F; Lütjohann D; Parhofer KG; Raal FJ; Ray KK; Remaley AT; Stock JK; Stroes ES; Tokgözoğlu L; Catapano AL
Lancet Diabetes Endocrinol; 2020 Jan; 8(1):50-67. PubMed ID: 31582260
[TBL] [Abstract][Full Text] [Related]
18. [Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011].
Soška V; Vaverková H; Vráblík M; Bláha V; Cífková R; Freiberger T; Kraml P; Piťha J; Rosolová H; Stulc T; Urbanová Z
Vnitr Lek; 2013 Feb; 59(2):120-6. PubMed ID: 23461401
[TBL] [Abstract][Full Text] [Related]
19. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
[TBL] [Abstract][Full Text] [Related]
20. [Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.].
Bubnova MG; Kukharchuk VV
Kardiologiia; 2017 Mar; 57(3):85-89. PubMed ID: 28762942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
